

#### Clinical Effectiveness, Clinical Utility and Comparative Effectiveness: An Evolving Landscape

Gurvaneet Randhawa, MD, MPH Center for Outcomes and Evidence Senior Advisor on Clinical Genomics and Personalized Medicine

SACGHS: June, 2009



## " In theory, theory is just like practice. In practice, it ain't."

Yogi Berra



Three major hurdles:
Pre-clinical to clinical efficacy
Clinical efficacy to effectiveness
Effectiveness to implementation & use



Observed benefits and harms of an intervention in clinical practice differs from expected (from efficacy studies)





### Patient Factors Influencing Effectiveness of Therapies

# Biology

- Age
- Sex
- Co-morbidities
- Disease severity
- Genetic variations
- Other: adherence, cost, preferences, drug-drug interactions



### Other Factors Influencing Effectiveness

- Natural history of disease
- surrogate vs. health outcomes
- Provider: training/skills, experience (e.g. volume of procedures), preferences, time, coverage, liability
- Hospital: volume, availability of devices/tests/therapies, specialty care (e.g. anticoagulation clinics)



# **Example: Warfarin**

Reduces thromboembolic events
 Commonly prescribed
 Narrow therapeutic index: excessive anti-coagulation can lead to bleeding
 Challenges: INR monitoring, drug-drug and diet-drug interactions, adherence



# **INR Monitoring**

■ Target range: week – 85%, month – 50% Self-monitoring may be useful Meta-analysis of 14 RCTs on selfmonitoring (± self-adjusting dose) shows: SM: 

main INR in target range (6/11-signf.) SM: 1 thromboembolic events (OR=0.45) SM: J major hemorrhage (OR=0.65) SM:  $\downarrow$  mortality (OR=0.61)

Lancet 2006; 267:404-11



### Distinguishing Effectiveness from Efficacy Trials

- Primary care population
- Stringency of inclusion/exclusion criteria
- Health outcomes
- Length of study
- Assessment of adverse events
- Adequate sample size
- Intention to treat analysis

AHRQ EPC report, 2006





#### Efficacy trials: high internal validity, poor applicability, small sample, fast, less cost

#### Effectiveness trials: high applicability, large sample, slow, expensive



### Health Utility: Outcome Measure

- Measures preference for health state [perfect health=1, death=0]
- Can be measured as an outcome in a study
- Calculate quality-adjusted life year (QALY), DALY etc.
- QALY often used in modeling studies (DA, CEA) to compare different interventions



# **Clinical Utility**

EGAPP: includes effectiveness and net benefit, sometimes efficacy

Examples: health outcomes, information useful for clinical decision making, end diagnostic odyssey, improve adherence Genetics in Medicine; 2009

Conceptually closer to a "decision" rather than "outcome" of an intervention



Efficacy: outcomes in ideal setting
Effectiveness: outcomes in real-world
Comparative efficacy (head-head trials)
Comparative effectiveness



- What are the (health) benefits?
- What are the harms?
- Will there be net benefit in the real-world?
- What is the incremental benefit?
- What is the feasibility?
- What is the cost-effectiveness and cost?
- Other issues: preferences, convenience, coverage/reimbursement etc.





USPSTF recommendations in absence of RCT data
 - cervical cancer screening
 - PKU screening
 EPC report on obesity Rx:
 - surgery more effective for BMI>40

#### AHRQ website



#### What?

Clinical interventions: test, device, drug, dietary supplement, biologic, surgical procedure, counseling/behavioral intervention etc.



# Methods (how?)

#### Design:

- a) Experimental: RCT (head-to-head, effectiveness), cluster randomized trials
- b) Observational: cohort, case-control
- c) Modeling
- d) Systematic reviews, meta-analyses
- Analytic techniques: approaches to minimize bias and confounding (improve internal validity)



### Comparative Effectiveness Research at AHRQ

Created in 2005, authorized by Section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003

AHRQ shall conduct and support research on:

- "the outcomes, comparative clinical effectiveness, and appropriateness of health care items and services (including prescription drugs)"
- Goal: to provide patients, clinicians and policy makers with reliable, evidence-based healthcare information




# Effective Health Care Program

- To improve the quality, effectiveness, and efficiency of health care delivered through Medicare, Medicaid, and S-CHIP programs
  - Focus is on what is known *now*: ensuring programs benefit from *past* investments in research and what research *gaps* are critical to fill
  - Focus is on *clinical effectiveness*



### **Conceptual Framework**







Number 12

#### Effective Health Care

Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis

#### **Executive Summary**

#### Background

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. The clinical complications of osteoporosis include fractures, disability, and chronic pain. Approximately 44 million people in the United States are affected by osteoporosis or low bone density. It is

#### **Effective Health Care Program**

The Effective Health Care Program was initiated in 2005 to provide valid evidence about the comparative effectiveness of different medical interventions. The object is to help consumers, health care providers, and others in making informed choices among treatment alternatives. Through its Comparative Effectiveness Reviews,



Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes Executive Summary

#### Background

Type 2 diabetes is characterized by insulin resistance accompanied by progressive deficiency in insulin secretion. Type 2 diabetes is an increasingly common disease that is closely associated with obesity. In 2005, the prevalence of Americans with diagnosed type 2 diabetes was 2.4 percent for adults aged 20-39 years, 10 percent for adults aged 40-59 years, and 21 percent for adults aged 60 years or over. From 1980 through 2004, the number of Americans diagnosed with diabetes more than doubled, from 5.8 million to 14.7 million. Observational studies and clinical trials show that improved glycemic control reduces microvascular complications (e.g., complications involving the eyes, kidneys, or nerves) and may reduce macrovascular complications (e.g., heart attack); however, the effects of specific oral diabetes medications on these outcomes are less certain.

As new classes of medications have become available for the treatment of diabetes, chicking array of oral medications with different mechanisms of action. The first oral diabetes medications were suffory/ureas, which were introduced into the market in 1955. The second-generation suffory/ureas, which are used looky, were suffory/ureas, which are used looky.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care + www.ahre.gov

#### Effective Health Care Program

The Effective Health Care Program was initiated in 2005 to provide valid. evidence about the comparative effectiveness of different medical interventions. The object is to help consumers, health care providers, and others in making informed choices among treatment alternatives. Through its Comparative Effectiveness Reviews, the program supports systematic appraisals of existing scientific evidence resarcing treatments for high-priority health conditions. It also promotes and generates new scientific evidence by identifying gaps in existing scientific evidence and supporting new research. The program puis special emphasis on translating findings into a variety of useful formats for different stakeholders, including consumers.


The full report and this summary are available at www.effectivehealthcare. ahrq.gov/reports/final.cfm

Effective Health Care



# **Educating Clinicians**

Concise
Actionable
Paired with consumer guides
Convey level of uncertainty/certainty of findings



are forwards and foreity



# **Challenge of Genomics**

- Large volume of gene-based information
   Relatively quick and easy to generate
   Little information on outcomes
   Paucity of information on added value
   Concern of rapid and inappropriate dissemination
- Limited skills and training of providers to tackle genomics, especially primary care
   Healthcare system is ill-equipped



# **Future Steps**

- Randomized effectiveness trials when feasible
- Improve observational study design and analysis methods to minimize bias and confounding (improve internal validity)
- Invest in electronic infrastructure to enhance clinical data collected for studies
  - example distributed research methods
- Consistency and transparency in using comparative effectiveness to make decisions
- Build public-private partnerships (CED?)
- Invest in clinical decision support tools



# Thank you!

# Effective Health Care: <a href="http://effectivehealthcare.ahrg.gov">http://effectivehealthcare.ahrg.gov</a>